

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **MicroPort CardioFlow Medtech Corporation**

**微创心通医疗科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2160)**

### **PROFIT FORECAST FOR THE FIRST HALF OF 2024 — SIGNIFICANT REDUCTION IN NET LOSS OF APPROXIMATELY 63% TO 72%**

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**” or “**our**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary review of the unaudited management accounts of the Group for the six months ended June 30, 2024 (the “**Reporting Period**”) and an assessment of the latest information currently available to the Board, the Group is expected to record a net loss of approximately RMB50 million to RMB65 million for the Reporting Period, representing a decrease of approximately 63% to 72% as compared to that for the six months ended June 30, 2023. Such decrease in net loss is mainly attributable to:

- (i) an increase in revenue of approximately 22% to 28% as compared to the corresponding period last year driven by the effect of continued advancement of our transcatheter aortic heart valve implantation (“**TAVI**”) products in terms of global commercialization, as well as the progress of commercialization of AnchorMan<sup>®</sup> LAA occluder system and its guidance system in the PRC;
- (ii) economies of scale brought along by the growth of sales of the Group’s products, and our continuous supply chain improvement, both driving a reduction in production costs and an increase in gross profit margins of over four percentage points as compared to the corresponding period last year; and

- (iii) the Group's endeavors in coordinating internal and external resources, leveraging intensive effect, and enhancing operational efficiency, driving the business to achieve healthy and sustainable growth.

Looking forward, the Group will further enrich its product portfolio and actively expand its income sources, with an aim to achieve break-even in 2025.

As the Company is still in the process of finalising the interim results of the Group for the six months ended June 30, 2024, the information contained in this announcement is only based on a preliminary assessment of the unaudited consolidated management accounts and relevant revenue and expense estimates made available to the Board as of the date of this announcement, which have not been audited or reviewed by the Company's auditors or reviewed by the audit committee of the Company, and the above information may be subject to adjustments. Further details of the Group's financial information will be disclosed in the Group's interim results announcement for the six months ended June 30, 2024, which is expected to be published in August 2024 according to the Listing Rules.

**Shareholders and potential investors are advised to exercise due care when dealing in the shares of the Company.**

By Order of the Board  
**MicroPort CardioFlow Medtech Corporation**  
**Chen Guoming**  
*Chairman*

Shanghai, the PRC, July 24, 2024

*As of the date of this announcement, the executive Directors are Mr. Jeffrey R Lindstrom, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.*